logo
How Healthcare Is Becoming Less Affordable Under The Trump Administration

How Healthcare Is Becoming Less Affordable Under The Trump Administration

Forbes16 hours ago
Ryan Chelsea-Clinton Community Health Center located in the Hell's Kitchen, New York City, provides ... More high-quality, affordable, and comprehensive healthcare services to children, adults, and seniors. (Photo by: Deb Cohn-Orbach/UCG/Universal Images Group via Getty Images)
It has been just six months since President Trump has started his second term as Commander-in-Chief, and there have been profound changes in the healthcare landscape across America. His legislative and regulatory agenda could accelerate the decline in healthcare affordability across the United States. Here's how health services and accessibility could be compromised for millions of Americans.
Medicaid Cuts
More than 10 million Americans will lose healthcare insurance coverage through Medicaid over the next decade as part of the 'One Big Beautiful Bill', according to the nonpartisan Congressional Budget Office. These millions of Americans are among the most vulnerable population in dire need of healthcare, as Medicaid supports children, the elderly, pregnant women and those with disabilities.
Without health insurance, individuals may be reluctant to seek care when sick, they may not go to the doctor's office for routine checkups, and they may not be able to fill drug prescriptions to curb serious diseases. When getting emergent care, these individuals will not be able to afford the large health bills they receive since they are uninsured as Medicaid will not contribute to picking up the tab.
Rollback Of Affordable Care Act Subsidies
President Joe Biden allowed for federal subsidies and premium tax credits for middle- and low-income families who bought state health coverage on state insurance marketplaces as part of the Affordable Care Act. This aid decreased medical bills and lowered insurance premiums for the 24 million Americans that benefit from this plan. These subsidies are in jeopardy and could expire in December if congress does not renew them.
If congress does not act, millions of Americans could be forced to lose healthcare coverage altogether or be pushed to switch to higher deductible health plans that would require them to pay more out of pocket costs before receiving financial support. These changes will not just affect low-income families. The cost to middle-class and working families will be stark- some households earning around $65,000 could see annual health costs rise by over $2,300, and approximately 4.2 million people could lose health insurance altogether, according to the Washington Post.
Rising Out-Of-Pocket Costs
Healthcare costs that were once paid by health insurers could be shifted increasingly to individuals. As an example, consider COVID-19 vaccines that have traditionally been covered by the federal government or health insurers at no cost to the consumer. New federal guidelines for COVID-19 vaccines will allow health insurers to halt coverage of the vaccines, so patients themselves will have to cover the cost.
As an example, Secretary of Health and Human Services Robert F. Kennedy Jr. and the CDC have stated that COVID-19 vaccines will no longer be recommended for pregnant females. Health insurers are usually obliged to cover vaccines that are recommended by federal regulatory bodies. However, with the new federal recommendations, health insurers will be exempt from covering this service to select individuals, which will effectively shift the cost to Americans if they want to stay protected from COVID-19.
Increased Drug Costs
President Trump has announced an intent to impose tariffs in the range of 25-200% on pharmaceuticals to incentivize drug production in the United States. If implemented, this policy would be problematic since 80 percent of generic tablets consumed by Americans are manufactured outside the U.S. according to The Hill. Even a 25% tariff would increase U.S. drug prices by nearly $51 billion.
This, of course, would have devastating consequences for millions of Americans. Not only would this make healthcare even less affordable than it already is, but health outcomes would deteriorate. Many Americans would forego buying medicines, thereby exacerbating sickness and illness. Nine out of 10 people over the age of 65 rely on prescription drugs to maintain their well-being, according to the American Association of Retired Persons.
Although the Trump administration has touted executive actions that seek to improve health transparency and reduce drug costs, the broader legislative and regulatory agenda being imposed will make healthcare significantly less affordable to the average American. Many American families could lose health insurance, face higher premiums and pay greater out-of-pocket costs in the years to come.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump pauses export controls to bolster China trade deal, FT says
Trump pauses export controls to bolster China trade deal, FT says

Yahoo

time30 minutes ago

  • Yahoo

Trump pauses export controls to bolster China trade deal, FT says

(Reuters) -The U.S. has paused curbs on tech exports to China to avoid disrupting trade talks with Beijing and support President Donald Trump's efforts to secure a meeting with President Xi Jinping this year, the Financial Times said on Monday. The industry and security bureau of the Commerce Department, which oversees export controls, has been told in recent months to avoid tough moves on China, the newspaper said, citing current and former officials. Reuters could not immediately verify the report. The White House and the department did not respond to Reuters' requests for comment outside business hours. Top U.S. and Chinese economic officials are set to resume talks in Stockholm on Monday to tackle longstanding economic disputes at the centre of a trade war between the world's top two economies. Tech giant Nvidia said this month it would resume sales of its H20 graphics processing units (GPU) to China, reversing an export curb the Trump administration imposed in April to keep advanced AI chips out of Chinese hands over national security concerns. The planned resumption was part of U.S. negotiations on rare earths and magnets, Commerce Secretary Howard Lutnick has said. The paper said 20 security experts and former officials, including former deputy US national security adviser Matt Pottinger, will write on Monday to Lutnick to voice concern, however. "This move represents a strategic misstep that endangers the United States' economic and military edge in artificial intelligence," they write in the letter, it added.

Genentech and Roche Present New Insights in Alzheimer's Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC
Genentech and Roche Present New Insights in Alzheimer's Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC

Yahoo

time30 minutes ago

  • Yahoo

Genentech and Roche Present New Insights in Alzheimer's Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC

– Trontinemab's Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining <5% – – Design of the Phase III TRONTIER 1 and 2 studies of trontinemab in early symptomatic Alzheimer's disease featured, with initiation planned in 2025 – – Plans for new Phase III trial investigating trontinemab in preclinical Alzheimer's disease, in people at high risk of cognitive decline – – New real-world data support Elecsys pTau217 as a standalone blood test, comparable to a PET scan, for rule-in and rule-out identification of amyloid pathology – SOUTH SAN FRANCISCO, Calif., July 28, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer's development portfolio is being presented at the Alzheimer's Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify the comprehensive approach Roche is taking in addressing Alzheimer's across the entire patient journey. Featured oral presentations include the latest results from the ongoing Phase Ib/IIa Brainshuttle™ AD study, which continue to support rapid and robust reduction of amyloid plaques, and design of the Phase III TRONTIER 1 and 2 studies of investigational trontinemab for early symptomatic Alzheimer's disease, with initiation planned later this year. As part of its growing Alzheimer's development program, Roche announced today its plans for an additional Phase III trial to investigate trontinemab in preclinical Alzheimer's disease. The trial will focus on individuals at risk of cognitive decline, with the goal of potentially delaying or preventing the progression of the disease to symptomatic stages. "Alzheimer's disease represents one of the greatest challenges in healthcare today and tackling it requires early detection and effective therapeutics," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "Trontinemab is designed to target a key driver of Alzheimer's disease biology more effectively in the brain. Combining new treatment avenues with advanced diagnostics may enable earlier and potentially more effective intervention. With plans for Phase III trials in both early symptomatic and preclinical Alzheimer's disease, we are advancing science with the goal of delaying—and ultimately preventing—progression of this devastating condition." Late-breaking oral and poster presentations highlight the potential of Roche's Elecsys® pTau217 as a reliable and accessible blood-based biomarker test, providing comparable results to PET scan and cerebrospinal fluid (CSF) diagnostics for rule-in and rule-out diagnosis of amyloid pathology, a hallmark of Alzheimer's disease, across care settings. The test, which received Breakthrough Device Designation from the U.S. Food and Drug Administration last year, will also be utilized in Roche's TRONTIER studies. "Blood based testing for Alzheimer's disease has the potential to greatly improve patient access and decrease the time to definitive disease diagnosis," said Matt Sause, CEO of Roche Diagnostics. "Our data show that the Elecsys pTau217 test performs comparably to PET scans but can be performed with a simple blood draw and analyzed in a routine clinical laboratory. This has the potential to transform the diagnosis of Alzheimer's and provide clear answers to caregivers, patients, and their families." Up to 75% of people living with symptoms of Alzheimer's disease globally have not been diagnosed, and those who have, waited an average of 2.8 years, and even less have received any form of treatment. Diagnostics play a crucial role in addressing the global challenge of Alzheimer's, not only to detect and identify people with the disease early, even before the first symptoms, but also to rule out those who may or may not benefit from specific treatments. Pharmaceuticals In a 90-minute Featured Research session, designs were shared for the Phase III studies, TRONTIER 1 and 2, which will initiate later this year, investigating the efficacy and safety of investigational trontinemab in people with early Alzheimer's disease. The primary endpoint will measure the change in cognition and function based on the Clinical Dementia Rating – Sum of Boxes scale after 18 months of treatment. Secondary endpoints will include assessments of cognition, function, behavioral symptoms, and quality of life. A pre-screening study, TRAVELLER, based on a brief clinical assessment and a plasma biomarker, which will be identified using the Elecsys pTau217 test, has also been initiated, to enable broader community outreach and extend access to these trials to more diverse populations representative of Alzheimer's disease. New data on the latest results for trontinemab from the completed dose-expansion part of the 1.8 mg/kg and 3.6 mg/kg cohorts from the ongoing Phase Ib/IIa Brainshuttle AD study continued to show rapid and robust reduction of amyloid plaques in the brain as measured by amyloid positron emission tomography (PET). In the 3.6 mg/kg cohort, trontinemab reduced amyloid levels below the 24 centiloid positivity threshold in 91% of participants (n=49/54) after 28 weeks of treatment; 72% (n=39/54) achieved deep clearance below 11 centiloids. These data were reinforced by early and significant reductions in fluid biomarkers of Alzheimer's disease, including total tau, phosphorylated Tau (pTau)181, pTau217, and neurogranin measured in CSF and continues to show a favourable safety and tolerability profile. Amyloid-related imaging abnormalities-edema/effusion (ARIA-E) continued to be observed in <5% of participants (blinded data; N=4/149 across 1.8 and 3.6 mg/kg dose cohorts). All cases were radiographically mild, one was associated with mild and transient symptoms. Diagnostics Roche will present data on a new study comparing the pTau217/Ab42 plasma ratio to the high-throughput, fully automated Elecsys pTau217 assay. The presentation will report on the accuracy of these tools in detecting amyloid pathology. Together with the high throughput and full automation of the assay, these data will assess the potential of Elecsys pTau217 as an accurate standalone rule-in and rule-out test that could be scaled up for broad implementation in routine clinical practice worldwide. Additionally, results from a cohort-based model of healthcare utilization in the U.S. demonstrated that using the Elecsys® pTau181 blood-based rule-out test in primary care scenarios improved diagnostic accuracy and reduced resource use compared with the current standard-of-care clinical, cognitive and imaging tests. If made available in primary care settings, the Roche Elecsys® pTau181 blood test has the potential to reliably avoid the need for further confirmatory testing in nearly all people who receive a negative result. This will avoid the need for these people to undergo unnecessary testing using CSF or PET, which often come with long wait times and high cost, resulting in further delays to diagnosis and cost to healthcare systems. Medicine Abstract title Presentation number (type) Presentation date (session) Time Abstracts will be available on the AAIC website. Pharmaceuticals Next wave of innovation in Alzheimer's disease therapeutics: The value of novel active transport mechanisms Featured Research Session (FRS), Talk 1 Room 718 27 July 2025, 2pm - 3:30pm EDT Cath Mummery, Roberto Villaseñor, Jens Niewoehner, Scarlett Barker, Luka Kulic Latest results from the dose-expansion part (Part 2) of the Brainshuttle™ AD study of trontinemab in people with Alzheimer's disease Featured Research Session (FRS), Talk 2 Room 718 27 July 2025, 2pm - 3:30pm EDT Luka Kulic, Fabien Alcaraz, Gregory Klein, Stephen Salloway, Carsten Hofmann, João A. Abrantes, Stella Yilmaz, Denise Sickert, Maddalena Marchesi, Jakub Wojtowicz, Andres Schneider, Ruth Croney, David Agnew, Silke Ahlers, Paul Delmar, Hanno Svoboda, Iris Wiesel Interim biomarker results for trontinemab, a novel Brainshuttle™ antibody in development for the treatment of Alzheimer's disease Featured Research Session (FRS), Talk 3 Room 718 27 July 2025, 2pm - 3:30pm EDT Gregory Klein, Gil Rabinovici, Henrik Zetterberg, Matteo Tonietto, Tobias Bittner, Daria Rukina, Fabien Alcaraz, Carsten Hofmann, Maddalena Marchesi, Jakub Wojtowicz, Ruth Croney, David Agnew, João A. Abrantes, Franziska Schaedeli Stark, Silke Ahlers, Paul Delmar, Hanno Svoboda, Iris Wiesel, Luka Kulic TRONTIER 1 and TRONTIER 2: Pivotal trials of trontinemab in early symptomatic Alzheimer's disease Featured Research Session (FRS), Talk 4 Room 718 27 July 2025, 2pm - 3:30pm EDT Janice Smith, Catherine Mummery, Jeffrey L. Cummings, Gil Rabinovici, Stephen Salloway, Reisa Sperling, Henrik Zetterberg, Angeliki Thanasopolou, Christopher Lane, Paul Delmar, Gregory Klein, Ruth Croney, Jakub Wojtowicz, Carsten Hofmann, Luka Kulic, Hideki Garren Diagnostics Evaluating the Impact on Diagnostic Performance and Healthcare Resource Utilization of Introducing a plasma rule-out test in the Alzheimer's Disease Diagnostic Pathway Poster #102729 27 July 2025, 7:30am - 4:15pm EDT Sophie Roth, Gustaf Ortsäter, Joana Amorim Freire Location tbc Evaluating the Clinical Performance of the Elecsys pTau217 Plasma Immunoassay to Detect Amyloid Pathology in a Routine Clinical Practice Cohort Poster #96679 28 July 2025, 7:30am – 4:15pm EDT Sayuri Hortsch, Niels Borlinghaus, Alexander Jethwa, David Caley, Annunziata Di Domenico, Craig Ritchie Clinical performance and effect of pre-analytical variation of plasma pTau217 alone versus the plasma pTau217/Aβ42 ratio for the identification of amyloid pathology Oral Developing Topics #108585 3-23-DEV Developing Topics on Tau Biomarkers 29 July 2025, 2:00pm – 3:30pm EDT Christopher M. Rank, Joana Amorim Freire, Alexander Jethwa, Annunziata Di Domenico, Christina Rabe, Marc Suárez-Calvet, Colin L. Masters, Tobias Bittner Accuracy of cerebrospinal fluid biomarker ratios to determine amyloid positron-emission tomography status: a diagnostic test accuracy meta-analysis Poster #100941 28 July 2025, 7:30am – 4:15pm EDT Pablo Martinez-Lage, Eino Solje, Julian G. Martins, Sraboni Sarkar Equity in diagnosis through adequate clinical trial design in diagnostic performance studies Poster #102804 30 July 2025, 7:30am - 4:15pm EDT Imke Kirste, David Caley, Clara Quijano Rubio, Margherita Carboni Investigating Differences in Patients Enrolled in a Clinical Study Based on Referral Type Poster #108110 30 July 2025, 7:30am - 4:15pm EDT Sophie Roth, Laura Schlieker, Sayuri Hortsch, Joana Amorim Freire, David Caley About trontinemab Trontinemab is an investigational Brainshuttle bispecific 2+1 amyloid-beta targeting monoclonal antibody specifically engineered for enhanced access to the brain to enable rapid reduction of amyloid in people with Alzheimer's disease. Trontinemab is designed for the efficient transport across the blood-brain barrier to target aggregated forms of amyloid beta and remove amyloid plaques in the brain. The uniqueness of trontinemab is based on Roche's proprietary Brainshuttle technology combining an amyloid beta-binding antibody with a transferring receptor (TfR1) shuttle module. As a result, high central nervous system (CNS) exposure of trontinemab may be achieved at low doses, leading to a rapid and deep amyloid clearance. Due to its unique properties, trontinemab might unlock the full potential of disease-modifying monoclonal antibodies by effectively penetrating the brain and potentially leading to slowing of disease progression. About Roche in Alzheimer's Disease With more than two decades of scientific research in Alzheimer's disease, Roche is working towards a day when we can detect and treat the disease early, in order to slow down, stop or even prevent its progression to preserve what makes people who they are. Today, the company's Alzheimer's disease portfolio spans investigational medicines for different targets, types and stages of the disease, including trontinemab. On the diagnostics side, it also includes approved and investigational tools, including digital and blood-based tests and CSF assays, aiming to more effectively detect, diagnose and monitor the disease. Yet the global challenges of Alzheimer's disease go well beyond the capabilities of science, and making a meaningful impact requires collaboration both within the Alzheimer's community and outside of healthcare. Roche will continue to work together with numerous partners with the hope to transform millions of lives. About Genentech in Neuroscience Neuroscience is a major focus of research and development at Genentech. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases. Genentech and Roche are investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer's disease, Huntington's disease, Parkinson's disease and Duchenne muscular dystrophy. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today. About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit View source version on Contacts Media Contact: Meghan Hindman (650) 467-6800Advocacy Contact: Jenee Williams (650) 303-2958Investor Contacts: Loren Kalm (650) 225-3217Bruno Eschli +41616875284 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Doonesbury Comic Strips by Garry Trudeau - July 28, 1990
Doonesbury Comic Strips by Garry Trudeau - July 28, 1990

Washington Post

time32 minutes ago

  • Washington Post

Doonesbury Comic Strips by Garry Trudeau - July 28, 1990

........Trump on Jeffrey Epstein: "Somebody that nobody cares about."....Laura Loomer: "How come we can't talk about what a dumb lying bimbo Pam Blondi is?...How many more times is this woman going to get away with F-ing everything up before she is fired?"....Trump on Rosie O'Donnell: "She is a threat to humanity."....O'Donnell in response: "I still live rent-free in that collapsing brain of yours. I'm everything you fear: a loud woman, a queer woman, a mother who tells the truth, an American who got out of the country before you set it ablaze."....Trump on Elon Musk: "50% genius, 50% boy."....Steve Bannon: "Formerly known as Elon Musk, Elmo the not an American, you're a South we take enough time and prove the facts of that, you should be deported because it's a crime what you did -- among many."....Musk: "The fat, drunken slob called Bannon will go back to prison and this time for a long time. He has a lifetime of crime to pay for."....Tucker Carlson: "Why are my cities disgusting? I don't even want to go there. It smells like weed and halal food."....CA Gov. Gavin Newsom: "Kids running from tear gas, crying on the phone because their mother was just taken from the fields. Trump calls me 'Newscum' but he's the real scum."....Jonathan V. Last on Trump: "Reinventing ICE as the primary instrument of internal state power. ICE is more or less a national brute squad."...Ruth Ben-Ghiat on Trump: "Authoritarian leader cult is folding to his will."....CA Governor's press office on Stephen Miller: "This fascist cuck in DC continues his assault on democracy and the the Constitution hurt your feelings, Stephen. Cry harder."....Charlie Kirk on Texas flooding: "The death toll likely would not have been as high if it wasn't for DEI."....Dean Blundell on Trump: "An aging, increasingly incoherent, barely upright man."....Maureen Dowd: "Trump, who plays at being king, is not interested in virtue; only in humiliation, conflict, enrichment and revenge."....Tina Brown: "Out of Trump's ass, his ego, and his flawless media intuition, came: Let's bomb the shit out of Fordo."....John Cleese on Trump administration: "This is why dictatorships fail. Dictators always surround themselves with yes-people who are terrified to acquaint the dictator with reality."....Trump on Sen. Rand Paul: "His ideas are actually crazy (losers!). The people of Kentucky can't stand him."....VP JD Vance: "I empathize with Americans who are exhausted after 25 years of foreign entanglements in the Middle difference is that back then we had dumb presidents."....Andrew Sullivan: "A president who lies about everything all the time is singularly incapable of being a war president. People have to trust your word in a war. But Trump's word is toilet paper."....John Oliver on ICE agents: "These are criminal gangs,...bounty hunters making money for each body they manage to kidnap. They have quotas. You are their USA is sick."....WH Communications Director Steven Cheung: "The Nobel Peace Prize is illegitimate if President Trump -- the ultimate peace president -- is denied his rightful recognition of bringing harmony across the world."....Rep. MTG: "America is the greatest country in the world and I fight the nasty 'America Last' Democrats in Washington to keep it that way."....Trump on Democrats: "I hate them. I cannot stand them, because I really believe they hate our country."....Rep. Hakeem Jeffries on House passing Trump's BBB: "One big ugly is a crime scene."....Jonathan Alter: "Might as well tear down the Statue of LIberty and flush Emma Lazarus's poem down the toilet."....Garrison Keillor: "Every morning the news hits us like a baseball bat. How did this crook and clown achieve the White House so he could wage war on science, higher education, the Constitution, regulatory agencies, and the world economy, while redecorating the Oval Office to look like the Golden Nugget in Las Vegas?"....Trump supporter to reporter "We're not stupid. Donald Trump is a genius. That's what the J stands for.".... ........Trump on Jeffrey Epstein: "Somebody that nobody cares about."....Laura Loomer: "How come we can't talk about what a dumb lying bimbo Pam Blondi is?...How many more times is this woman going to get away with F-ing everything up before she is fired?"....Trump on Rosie O'Donnell: "She is a threat to humanity."....O'Donnell in response: "I still live rent-free in that collapsing brain of yours. I'm everything you fear: a loud woman, a queer woman, a mother who tells the truth, an American who got out of the country before you set it ablaze."....Trump on Elon Musk: "50% genius, 50% boy."....Steve Bannon: "Formerly known as Elon Musk, Elmo the not an American, you're a South we take enough time and prove the facts of that, you should be deported because it's a crime what you did -- among many."....Musk: "The fat, drunken slob called Bannon will go back to prison and this time for a long time. He has a lifetime of crime to pay for."....Tucker Carlson: "Why are my cities disgusting? I don't even want to go there. It smells like weed and halal food."....CA Gov. Gavin Newsom: "Kids running from tear gas, crying on the phone because their mother was just taken from the fields. Trump calls me 'Newscum' but he's the real scum."....Jonathan V. Last on Trump: "Reinventing ICE as the primary instrument of internal state power. ICE is more or less a national brute squad."...Ruth Ben-Ghiat on Trump: "Authoritarian leader cult is folding to his will."....CA Governor's press office on Stephen Miller: "This fascist cuck in DC continues his assault on democracy and the the Constitution hurt your feelings, Stephen. Cry harder."....Charlie Kirk on Texas flooding: "The death toll likely would not have been as high if it wasn't for DEI."....Dean Blundell on Trump: "An aging, increasingly incoherent, barely upright man."....Maureen Dowd: "Trump, who plays at being king, is not interested in virtue; only in humiliation, conflict, enrichment and revenge."....Tina Brown: "Out of Trump's ass, his ego, and his flawless media intuition, came: Let's bomb the shit out of Fordo."....John Cleese on Trump administration: "This is why dictatorships fail. Dictators always surround themselves with yes-people who are terrified to acquaint the dictator with reality."....Trump on Sen. Rand Paul: "His ideas are actually crazy (losers!). The people of Kentucky can't stand him."....VP JD Vance: "I empathize with Americans who are exhausted after 25 years of foreign entanglements in the Middle difference is that back then we had dumb presidents."....Andrew Sullivan: "A president who lies about everything all the time is singularly incapable of being a war president. People have to trust your word in a war. But Trump's word is toilet paper."....John Oliver on ICE agents: "These are criminal gangs,...bounty hunters making money for each body they manage to kidnap. They have quotas. You are their USA is sick."....WH Communications Director Steven Cheung: "The Nobel Peace Prize is illegitimate if President Trump -- the ultimate peace president -- is denied his rightful recognition of bringing harmony across the world."....Rep. MTG: "America is the greatest country in the world and I fight the nasty 'America Last' Democrats in Washington to keep it that way."....Trump on Democrats: "I hate them. I cannot stand them, because I really believe they hate our country."....Rep. Hakeem Jeffries on House passing Trump's BBB: "One big ugly is a crime scene."....Jonathan Alter: "Might as well tear down the Statue of LIberty and flush Emma Lazarus's poem down the toilet."....Garrison Keillor: "Every morning the news hits us like a baseball bat. How did this crook and clown achieve the White House so he could wage war on science, higher education, the Constitution, regulatory agencies, and the world economy, while redecorating the Oval Office to look like the Golden Nugget in Las Vegas?"....Trump supporter to reporter "We're not stupid. Donald Trump is a genius. That's what the J stands for.".... ........Trump on Jeffrey Epstein: "Somebody that nobody cares about."....Laura Loomer: "How come we can't talk about what a dumb lying bimbo Pam Blondi is?...How many more times is this woman going to get away with F-ing everything up before she is fired?"....Trump on Rosie O'Donnell: "She is a threat to humanity."....O'Donnell in response: "I still live rent-free in that collapsing brain of yours. I'm everything you fear: a loud woman, a queer woman, a mother who tells the truth, an American who got out of the country before you set it ablaze."....Trump on Elon Musk: "50% genius, 50% boy."....Steve Bannon: "Formerly known as Elon Musk, Elmo the not an American, you're a South we take enough time and prove the facts of that, you should be deported because it's a crime what you did -- among many."....Musk: "The fat, drunken slob called Bannon will go back to prison and this time for a long time. He has a lifetime of crime to pay for."....Tucker Carlson: "Why are my cities disgusting? I don't even want to go there. It smells like weed and halal food."....CA Gov. Gavin Newsom: "Kids running from tear gas, crying on the phone because their mother was just taken from the fields. Trump calls me 'Newscum' but he's the real scum."....Jonathan V. Last on Trump: "Reinventing ICE as the primary instrument of internal state power. ICE is more or less a national brute squad."...Ruth Ben-Ghiat on Trump: "Authoritarian leader cult is folding to his will."....CA Governor's press office on Stephen Miller: "This fascist cuck in DC continues his assault on democracy and the the Constitution hurt your feelings, Stephen. Cry harder."....Charlie Kirk on Texas flooding: "The death toll likely would not have been as high if it wasn't for DEI."....Dean Blundell on Trump: "An aging, increasingly incoherent, barely upright man."....Maureen Dowd: "Trump, who plays at being king, is not interested in virtue; only in humiliation, conflict, enrichment and revenge."....Tina Brown: "Out of Trump's ass, his ego, and his flawless media intuition, came: Let's bomb the shit out of Fordo."....John Cleese on Trump administration: "This is why dictatorships fail. Dictators always surround themselves with yes-people who are terrified to acquaint the dictator with reality."....Trump on Sen. Rand Paul: "His ideas are actually crazy (losers!). The people of Kentucky can't stand him."....VP JD Vance: "I empathize with Americans who are exhausted after 25 years of foreign entanglements in the Middle difference is that back then we had dumb presidents."....Andrew Sullivan: "A president who lies about everything all the time is singularly incapable of being a war president. People have to trust your word in a war. But Trump's word is toilet paper."....John Oliver on ICE agents: "These are criminal gangs,...bounty hunters making money for each body they manage to kidnap. They have quotas. You are their USA is sick."....WH Communications Director Steven Cheung: "The Nobel Peace Prize is illegitimate if President Trump -- the ultimate peace president -- is denied his rightful recognition of bringing harmony across the world."....Rep. MTG: "America is the greatest country in the world and I fight the nasty 'America Last' Democrats in Washington to keep it that way."....Trump on Democrats: "I hate them. I cannot stand them, because I really believe they hate our country."....Rep. Hakeem Jeffries on House passing Trump's BBB: "One big ugly is a crime scene."....Jonathan Alter: "Might as well tear down the Statue of LIberty and flush Emma Lazarus's poem down the toilet."....Garrison Keillor: "Every morning the news hits us like a baseball bat. How did this crook and clown achieve the White House so he could wage war on science, higher education, the Constitution, regulatory agencies, and the world economy, while redecorating the Oval Office to look like the Golden Nugget in Las Vegas?"....Trump supporter to reporter "We're not stupid. Donald Trump is a genius. That's what the J stands for."....

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store